Funding: this work was supported by several funding agencies. The PanACEA MAMS study was funded by the European and Developing Countries Clinical Trials Partnership (EDCTP1); Grant No. IP.2007.32011.013, IP.2007.32011.012, and IP.2007.32011.011 as well as by the German Ministry of Education and Research (01KA0901). This analysis was funded by the German Center for Infection Research (DZIF); grant no. 02.702.Bacterial killing in patients with tuberculosis (TB) relapse was compared to that in patients achieving cure, measured by TB molecular bacterial load assay (TB-MBLA) or mycobacteria growth indicator tube (MGIT) time to positivity (TTP). TB-MBLA in 4 relapsed patients was significantly different compared to 132 cured patients after 2 week...
Although Mycobacterium tuberculosis is eradicated rapidly during therapy in some patients with pulmo...
Background: Clinical symptoms are the benchmark of tuberculosis (TB) diagnosis and monitoring of tre...
Rifampin or multidrug-resistant tuberculosis (RR/MDR-TB) treatment has largely transitioned to regim...
Bacterial killing in patients with tuberculosis (TB) relapse was compared to that in patients achiev...
Bacterial killing in TB-patients with relapse was compared to patients achieving cure, measured by T...
This work was supported by the European and Developing Countries Clinical Trials Partnership (EDCTP)...
Authors acknowledge financial support from the EDCTP2 programme supported by the European Union proj...
Background: New treatment options are needed to maintain and improve therapy for tuberculosis, which...
Molecular bacterial load assay (MBLA) rapidly quantifies viable Mycobacterium tuberculosis (Mtb) and...
Contains fulltext : 136117.pdf (publisher's version ) (Open Access)We evaluated th...
Background Identification of patients at risk of tuberculosis relapse following treatment would revo...
In this comparative biomarker study, we analysed 1768 serial sputum samples from 178 patients at 4 s...
Funding: European and Developing Countries Clinical Trials Partnership (EDCTP) – Pan African Biomark...
In this comparative biomarker study, we analysed 1768 serial sputum samples from 178 patients at 4 s...
Mycobacterium tuberculosis (Mtb) is extremely recalcitrant to antimicrobial chemotherapy requiring 6...
Although Mycobacterium tuberculosis is eradicated rapidly during therapy in some patients with pulmo...
Background: Clinical symptoms are the benchmark of tuberculosis (TB) diagnosis and monitoring of tre...
Rifampin or multidrug-resistant tuberculosis (RR/MDR-TB) treatment has largely transitioned to regim...
Bacterial killing in patients with tuberculosis (TB) relapse was compared to that in patients achiev...
Bacterial killing in TB-patients with relapse was compared to patients achieving cure, measured by T...
This work was supported by the European and Developing Countries Clinical Trials Partnership (EDCTP)...
Authors acknowledge financial support from the EDCTP2 programme supported by the European Union proj...
Background: New treatment options are needed to maintain and improve therapy for tuberculosis, which...
Molecular bacterial load assay (MBLA) rapidly quantifies viable Mycobacterium tuberculosis (Mtb) and...
Contains fulltext : 136117.pdf (publisher's version ) (Open Access)We evaluated th...
Background Identification of patients at risk of tuberculosis relapse following treatment would revo...
In this comparative biomarker study, we analysed 1768 serial sputum samples from 178 patients at 4 s...
Funding: European and Developing Countries Clinical Trials Partnership (EDCTP) – Pan African Biomark...
In this comparative biomarker study, we analysed 1768 serial sputum samples from 178 patients at 4 s...
Mycobacterium tuberculosis (Mtb) is extremely recalcitrant to antimicrobial chemotherapy requiring 6...
Although Mycobacterium tuberculosis is eradicated rapidly during therapy in some patients with pulmo...
Background: Clinical symptoms are the benchmark of tuberculosis (TB) diagnosis and monitoring of tre...
Rifampin or multidrug-resistant tuberculosis (RR/MDR-TB) treatment has largely transitioned to regim...